Station Houston is hosting a tech job fair on Tuesday, February 19. Station Houston/Facebook

Houston is a great place to grow, thanks to the low cost of living, booming job market and strong economy. In fact, a recent study predicted that Houston will end the year with 3.2 million payroll jobs – a net increase of more than 600,000 jobs over the past decade. In Houston (which recently nearly matched Austin in VC funding), the dollar goes much further than other tech-centric markets like Silicon Valley, making it more attractive for startups and technology companies to grow here too.

With new employers Amazon Web Services and Bill.com, among others, Houston's innovation scene is thriving and needs to fill jobs. That's where Station Houston, Houston's hub for tech startups, entrepreneurs and innovation, comes in with its hiring event, Startup Gigs, on Tuesday, February 19.

Details
At Startup Gigs, Station will bring engineering, product, sales, marketing, and design professionals together with Houston's community of growing startups. The goal of the event is to reach untapped talent and industry experts interested in joining a startup and or tech team. Did we mention it's free to attend?

Date: Tuesday, February 19, 2019
Time: 5:30 to 7 pm
Register here.

Who's Hiring?

Startups:

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”